Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTREPID: Skin Sodium and Salt Sensitivity in Hypertension
NCT05976438Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of chlorthalidone in hypertension (HTN) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Concentration of Skin sodium at 16 weeks, Concentration of Skin Potassium at 16 weeks and 1 more. Status: unknown.
02
Drugs
chlorthalidone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05976438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976438.